clinical trial · NCT06063473
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris
Sun Pharmaceutical Industries, Inc.·phase1·completed·n = 762
Acne VulgarisTrifarotene Cream 0.005%PlaceboAKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories)
brief summary
To demonstrate therapeutic equivalence and safety of Trifarotene cream 0.005% (Taro Pharmaceuticals U.S.A., Inc.) and AKLIEF® cream in the treatment of acne vulgaris
started
Feb 22, 2023
primary completion
Jul 13, 2023
completion
Jul 13, 2023
last updated
Oct 2, 2023
detailed description
A multi-center, double-blind, randomized, placebo-controlled, parallel-group study, comparing Trifarotene Cream 0.005% (Taro Pharmaceuticals U.S.A., Inc.) to AKLIEF® Cream and both active treatments to a placebo control in the treatment of acne vulgaris
official title
A Multi-center, Double-blind, Randomized, Placebo Controlled, Parallel-group Study, Comparing Trifarotene Cream 0.005% (Taro Pharmaceuticals U.S.A, Inc.) and to AKLIEF® Cream (Trifarotene 0.005%,Galderma) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol